IMNN
ImunonANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The post-earnings bull case is that May 12 strengthened the clinical narrative: management reiterated ahead-of-plan OVATION 3 enrollment, FDA protocol alignment, and a path to BLA filing, while final Phase 2 data continued to show a large overall-survival delta [#8-K-2026-05-12][#10-Q-2026-05-12].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Dilution risk is high because the company expanded ATM capacity in March 2026 and disclosed post-quarter-end ATM issuance proceeds, even after no Q1 ATM sales [#10-Q-2026-05-12].
Momentum
93
Value
41
Sentiment
76
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.30 · Bull $5.50 · Bear $1.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $17.67
Why
Momentum93 · Δ7d -
Value41 · Δ7d +0.1
Sentiment76 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
93
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
76
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 93.5 / Value 41.1 / Sentiment 75.9
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$9.04M
Beta
2.13
Shares Out
3.07M
P/E (TTM) · Derived
-0.1
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.35
Rev YoY
-
EPS YoY
+76.8%
Gross Margin
-
Op Margin
-
Net Debt
-$5.87M
Current Ratio
1.73
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology